* BIOVERATIV’S INVESTIGATIONAL BIVV009 DEMONSTRATES SAFETY, TOLERABILITY AND EFFICACY IN PHASE 1B CLINICAL TRIAL IN COLD AGGLUTININ DISEASE (CAGD) PATIENTS

* BIOVERATIV INC - PHASE 1B RESULTS ACHIEVE PRIMARY AND SECONDARY ENDPOINTS IN CAGD COHORT

* BIOVERATIV - FOUND STATISTICALLY SIGNIFICANT OVERALL INCREASED RATE OF THROMBOEMBOLIC EVENTS IN CAGD PATIENTS VERSUS MATCHED CONTROLS Source text for Eikon: Further company coverage: